ArticleNeurogenetics2026
The recurrent SACS gene p.Arg272His hotspot expands the neurodevelopmental and cognitive spectrum of ARSACS.
Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a rare neurodegenerative disorder caused by pathogenic variants in the SACS gene. While traditionally defined by a motor triad, emerging evidence suggests a broader phenotypic spectrum that includes significant cognitive involvement. We describe a 16-year-old Sicilian female, born to consanguineous parents, and homozygous for missense variant c.815G > A (p.Arg272His). Alongside the classical triad of progressive cerebellar ataxia, pyramidal spasticity, and demyelinating sensorimotor polyneuropathy, the patient exhibited mild intellectual disability (ID) with a Full-Scale Intelligence Quotient (IQ) of 60. Additional clinical markers included early-onset axial hypotonia and marked retinal nerve fiber layer thickening on optical coherence tomography. Longitudinal neuroimaging over 13 years documented progressive cerebellar vermis atrophy and the emergence of pontine transverse fiber hyperintensity. Comparison with previously published patients carrying the identical homozygous variant strongly supports p.Arg272His as a recurrent mutational hotspot involving a highly conserved functional residue within the SIRPT1 domain of sacsin, likely critical for mitochondrial homeostasis and neuronal cytoskeletal organization. Importantly, comparison with previously reported patients suggests that cognitive impairment and intellectual disability may represent recurrent and potentially under-recognized features among individuals carrying the p.Arg272His variant, although the limited number of reported cases precludes definitive genotype-phenotype conclusions. This case adds longitudinal clinical, neuroimaging, ophthalmological, and neuropsychological data to the limited literature on patients carrying the p.Arg272His variant, supporting further investigation of genotype-phenotype relationships in ARSACS. We advocate for the integration of standardized neuropsychological assessments into the routine diagnostic workup for ARSACS to ensure comprehensive patient management.
Indexed as
Identifiers
42671486What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.